Filament Health Announces Private Placement And Intention To Voluntarily Delist From Cboe Canada
Summary
Financing driven by existing investor Negev and Filaments Board of DirectorsCompany also announces intention to voluntarily delist from Cboe CanadaVancouver, British Columbia, April 3, 2025 Filament Health Corp. (OTCQB:FLHLF) (Cboe CA:FH) (FSE:7QS) (Filament or the Company), a clinicalstage natural psychedelic drug development company, today announces a financing led by Negev Capital Fund One, LP (Negev), a leading psychedelic drug development venture fund and existing investor in the Company, Benjamin Lightburn, the Chairman of the Board, Chief Executive Officer and Co-Founder of the Company, and Michael Messinger, a member of the Board (the Financing). Filament remains well-positioned, leveraging its groundbreaking botanical drug development platform and an industry-leading intellectual property portfolio.Filament also announced that it intends to voluntarily delist its common shares from Cboe Canada, after obtaining necessary shareholder approval in an upcoming Special Meeting scheduled for May 6, 2025. Furthermore, the expense and administrative requirements associated with maintaining the listing on the Cboe Canada are no longer tenable given the trading volume of its common shares on the exchange. The net proceeds of the financing will provide additional financial flexibility for the Company.Filament Health is a clinical-stage natural psychedelic drug development company. Filament will not update any forward looking statements or forwardlooking information that are incorporated by reference herein, except as required by applicable securities laws.